Bayer raises FY guidance on pharma strength despite Q3 net loss

Bayer lifted its full-year adjusted EBITDA guidance by €200M to €9.8-10.3B and raised its pharma division margin outlook to 25-27%, citing a turning point in prescription drug growth. The company still posted a net loss in Q3, but the guidance upgrade signals improved operational momentum in its core pharma segment. The market impact is company-specific, with no clear macro-directional signal.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works